92: [177Lu]Lu-Dota-Tate as First-Line Therapy for Patients with Grade 2 and 3 Advanced Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETS): The NETTER-2 Study. (September 2022) - Myrehaug, Sten; Singh, Simron; Pavel, Marianne; Kunz, Pamela; de Herder, Wouter; Herrmann, Ken; D'Amelio, Anthony; Santoro, Paola; Folitar, Ilya; Ferone, Diego